Oncology Pharmacy - Questions Needed

HIGHEST PRIORITY

Domain 2 — Interpret, generate, and/or disseminate knowledge in oncology as it applies to oncology pharmacy practice.

02/01

Retrieve and evaluate relevant oncology literature

02/04

Provide formal and informal education and consultation to the professional community and assess the effectiveness of these activities. K-17   oncology literature and information retrieval systems K-18   study design and methodology K-19   common study endpoints (e.g., response, adverse events, economics, quality of life, pharmacokinetics, pharmacodynamics) K-20:   Selective strengths and limitations of different study designs K-26   oncology drug development process

Domain 3 — In collaboration with other professionals, patients, and the public, recommend, design, implement, monitor, and modify systems and policies to optimize the use of drugs in patients with cancer.

03/02

Assess/Evaluate pharmacy services provided to patients with cancer for compliance with established standards and guidelines.

03/03

Share expertise with patients and the health-care community regarding regulatory and ethical issues related to patients rights (e.g., assisted suicide, confidentiality, informed consent, alternative therapies). K-28   Established methodology for developing clinical practice guidelines K-30   National accreditation, regulatory standards and legislation (e.g., JCAHO, HCFA, OSHA, OBRA, DEA, ASHP Oncology Pharmacy Practice Residency Standards) K-31   Reimbursement policies of federal and private agencies as related to the provision of care to patients with cancer K-32   Quality improvement strategies to avoid medication misadventures (e.g., processing of chemotherapy orders, protocol reviews) K-35   Medication utilization evaluation (MUE) process

Domain 4 — Collaborate with other professionals and the public in addressing public health issues (e.g. risk factors, prevention, screening, cancer survivorship) as they relate to oncology pharmacy practice

04/03

Advise and direct the public and consumers to appropriate resource groups, organizations, and agencies. K-37   Cancer prevention strategies K-39   Alternative treatment approaches for the prevention and treatment of cancer K-40   The impact of health-care systems on the availability of cancer prevention and treatment options.

LOWER PRIORITY

Domain 1 — Collaborate with other health professionals in pursuing optimal drug therapy for patients with cancer. This requires that the oncology pharmacist collects and interprets pertinent clinical data, and assumes personal responsibility for successful drug therapy outcomes.

01/02	Establish therapeutic goals in collaboration with the patient and other professionals.
01/07	Effectively document and communicate findings and recommendations regarding pharmacotherapeutic treatment with other professionals, patients and family.

Questions are needed to address any of the tasks within Domain 1 for:

Nutrition support/altered nutrition status
Psychosocial issues
Circadian drug delivery
Radiation sensitization

Also, questions are needed to update information (changes in last 1-2 years) within Domain 1 for:

Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer